MD4317B1 - Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure - Google Patents
Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failureInfo
- Publication number
- MD4317B1 MD4317B1 MDA20130064A MD20130064A MD4317B1 MD 4317 B1 MD4317 B1 MD 4317B1 MD A20130064 A MDA20130064 A MD A20130064A MD 20130064 A MD20130064 A MD 20130064A MD 4317 B1 MD4317 B1 MD 4317B1
- Authority
- MD
- Moldova
- Prior art keywords
- trimethylhydrazinium
- heart failure
- liver cirrhosis
- treating patients
- advanced liver
- Prior art date
Links
Abstract
The invention relates to medicine, particularly to hepatology.According to the invention, the use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate is claimed for treating advanced liver cirrhosis associated with heart failure, intravenously, 500 mg, 1…2 times a day, for 7…10 days, then per os, 500 mg, 1…2 times a day, for 4…6 weeks.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MDA20130064A MD4317C1 (en) | 2013-09-12 | 2013-09-12 | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MDA20130064A MD4317C1 (en) | 2013-09-12 | 2013-09-12 | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure |
Publications (2)
Publication Number | Publication Date |
---|---|
MD4317B1 true MD4317B1 (en) | 2015-01-31 |
MD4317C1 MD4317C1 (en) | 2015-08-31 |
Family
ID=52440946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20130064A MD4317C1 (en) | 2013-09-12 | 2013-09-12 | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure |
Country Status (1)
Country | Link |
---|---|
MD (1) | MD4317C1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4458C1 (en) * | 2014-06-19 | 2017-08-31 | Мария ДАНУ | Use of Polybiolin drug in patients with liver cirrhosis |
-
2013
- 2013-09-12 MD MDA20130064A patent/MD4317C1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4458C1 (en) * | 2014-06-19 | 2017-08-31 | Мария ДАНУ | Use of Polybiolin drug in patients with liver cirrhosis |
Also Published As
Publication number | Publication date |
---|---|
MD4317C1 (en) | 2015-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017010188A2 (en) | phospholipid ether analogues as cancer-targeting drug carriers | |
CY1122469T1 (en) | SUBLINGUAL PHARMACEUTICAL FORM OF RILOUZOLE | |
PH12016502352A1 (en) | Pharmaceutical composition | |
EA201791110A1 (en) | SUBLINGUAL INTRODUCTION OF RHYNESOL | |
EA201790726A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS | |
TW201613578A (en) | Pharmaceutical combinations | |
BR112016029012A2 (en) | method of treating non-small cell lung cancer and / or small cell lung cancer using thienotriazolodiazepine compounds | |
MX2016000294A (en) | Pharmaceutical composition for a sustained release of lanreotide. | |
MX357763B (en) | Treatment for pancreatic cancer. | |
SG11201804307WA (en) | Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same | |
BR112017002449A2 (en) | treatment of symptoms associated with androgen deprivation therapy | |
MD4317C1 (en) | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure | |
PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
MD4316C1 (en) | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis | |
WO2014153505A3 (en) | Treatment of chemotherapy-induced peripheral neuropathy | |
TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
MD4458C1 (en) | Use of Polybiolin drug in patients with liver cirrhosis | |
UA83408U (en) | Method for treatment of patients with chronic pancreatitis at comorbide cource of ischemic disease and syndrome of congestive heart failure | |
UA83410U (en) | Method for treatment of patients with chronic pancreatitis with ischemic heart disease at congestive heart failure | |
UA91605U (en) | Method for correcting disordered microcirculation in gastric mucosa of aged patients | |
PH12014000105A1 (en) | Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds | |
IN2014DE00822A (en) | ||
RU2015122823A (en) | METHOD FOR TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH HEPATIC CIRROSIS | |
IN2014DE00818A (en) | ||
UA96488U (en) | A method for treating disorders of hemovascular hemostasis in patients with ischemic heart disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG4A | Patent for invention issued | ||
KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
MM4A | Patent for invention definitely lapsed due to non-payment of fees |